CA2552758A1 - Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same - Google Patents

Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same Download PDF

Info

Publication number
CA2552758A1
CA2552758A1 CA002552758A CA2552758A CA2552758A1 CA 2552758 A1 CA2552758 A1 CA 2552758A1 CA 002552758 A CA002552758 A CA 002552758A CA 2552758 A CA2552758 A CA 2552758A CA 2552758 A1 CA2552758 A1 CA 2552758A1
Authority
CA
Canada
Prior art keywords
subject
cgrp
administered
hours
myocardial infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002552758A
Other languages
English (en)
French (fr)
Inventor
Jeffrey L. Southard
George Lee Southard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogenix Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2552758A1 publication Critical patent/CA2552758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002552758A 2004-01-13 2005-01-13 Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same Abandoned CA2552758A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56074504P 2004-01-13 2004-01-13
US60894504P 2004-01-13 2004-01-13
US60/608,945 2004-01-13
US60/560,745 2004-01-13
US56505604P 2004-04-23 2004-04-23
US60/565,056 2004-04-23
PCT/US2005/001230 WO2005070445A2 (en) 2004-01-13 2005-01-13 Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same

Publications (1)

Publication Number Publication Date
CA2552758A1 true CA2552758A1 (en) 2005-08-04

Family

ID=34812098

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002552758A Abandoned CA2552758A1 (en) 2004-01-13 2005-01-13 Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same

Country Status (6)

Country Link
US (1) US20090023643A1 (enExample)
EP (1) EP1703916A2 (enExample)
JP (1) JP2007517913A (enExample)
CA (1) CA2552758A1 (enExample)
TW (1) TW200538148A (enExample)
WO (1) WO2005070445A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
CA2699257A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Cgrp as a therapeutic agent
EP2802338B1 (en) 2012-01-09 2018-03-07 Serpin Pharma, LLC Peptides and methods of using same
EP3340974B1 (en) * 2015-08-28 2021-04-28 Serpin Pharma, LLC Peptides for the treatment of myocardial infarction
EP3911359A4 (en) * 2018-12-21 2022-11-16 Epoqe Pharma ApS COMPOUNDS FOR USE IN INDUCING MYOCARDIAL PERFUSION RECOVERY

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280825A (enExample) * 1962-07-11
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
EP0188400B1 (de) * 1985-01-16 1992-07-08 Ciba-Geigy Ag Oligopeptide sowie Zwischenprodukte und Verfahren zu ihrer Herstellung
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5190761A (en) * 1986-08-05 1993-03-02 Liburdy Robert P Electromagnetic field triggered drug and chemical delivery via liposomes
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
USRE37950E1 (en) * 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
JPH0789876A (ja) * 1993-09-20 1995-04-04 Shiseido Co Ltd 徐放性製剤
DK1125577T3 (da) * 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
WO1997027840A1 (en) * 1996-02-02 1997-08-07 Alza Corporation Sustained delivery of an active agent using an implantable system
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
AR015175A1 (es) * 1997-10-03 2001-04-18 Macromed Inc COMPOSICIoN ACUOSA BIODEGRADABLE POLIMÉRICA PARA LA ENTREGA DE UN FÁRMACO.
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DK1053020T3 (da) * 1998-01-29 2004-07-26 Poly Med Inc Absorberbare mikropartikler
DE69907870T2 (de) * 1998-01-29 2004-03-04 Kinerton Ltd., Blanchardstown Verfahren zur herstellung von absorbierbaren mikropartikeln
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
NZ512671A (en) * 1998-12-31 2003-12-19 Alza Corp Osmotic delivery system having space efficient piston
CA2277656C (en) * 1999-07-19 2010-04-27 Imax Corporation Image projection system
IL149008A0 (en) * 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
MXPA04007124A (es) * 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
JP2008512206A (ja) * 2004-09-09 2008-04-24 バイエル・ヘルスケア・エルエルシー 圧縮空気を使用するランセットの減勢システム

Also Published As

Publication number Publication date
JP2007517913A (ja) 2007-07-05
US20090023643A1 (en) 2009-01-22
WO2005070445A3 (en) 2006-10-12
WO2005070445A2 (en) 2005-08-04
EP1703916A2 (en) 2006-09-27
TW200538148A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
JP7700205B2 (ja) Ｇｉｐ／ｇｌｐ１アゴニスト組成物
ES2268710T3 (es) Uso de los dipeptidos glu-trp para la elaboracion de un medicamento para el tratamiento de diferentes condiciones que involucran neovasculacion.
ES2842210T3 (es) 4F-benzoil-TN14003 para la movilización de células progenitoras hematopoyéticas con vistas al trasplante
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
JP2014169310A (ja) Ｅｔｂ受容体アゴニストを用いた脳卒中または脳血管障害の治療方法
US7144577B2 (en) Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
EA009995B1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
AU2017213440A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
US20090023643A1 (en) Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same
US9333233B2 (en) Methods and compositions for the delayed treatment of stroke
EP1740201B1 (en) Pharmaceutical compositions comprising interferon-tau
US20220313777A1 (en) Inhaled delivery of peptide mimics of cxcl10 for targeted anti-fibrotic therapy
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
CA2738757A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
AU2005222085A2 (en) Treating or preventing extracellular matrix build-up
HK1223556B (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead